Metabolic Disorders and Neurodegenerative Disease Interactions

Metabolic disorders such as type 2 diabetes, obesity and dyslipidaemia share numerous pathogenic mechanisms with neurodegenerative conditions, including Alzheimer’s and Parkinson’s diseases. Impaired insulin signalling in the brain, chronic low‐grade inflammation and oxidative stress converge on neuronal and glial dysfunction, promoting accumulation of misfolded proteins, synaptic loss and vascular compromise. Adipose‐derived hormones (adipokines) and aberrant lipid metabolism exert direct effects on blood–brain barrier integrity and microglial activation, while central pathology likewise perturbs systemic glucose and lipid homeostasis. This bidirectional crosstalk underlies the heightened risk of cognitive decline in patients with metabolic syndromes and suggests that therapeutic strategies targeting metabolic pathways may ameliorate neurodegenerative progression. The global burden of ageing populations and rising prevalence of diabetes emphasises the urgent need to understand these interactions and develop interventions with dual metabolic and neuroprotective benefits.

Research from Nature Portfolio

Researchers have demonstrated that treatment with a plant‐derived adiponectin analogue can reverse established amyloid-β-induced synaptic deficits and cognitive impairment in preclinical models. Systemic administration of the protein led to restoration of PI3K/Akt signalling, inhibition of glycogen synthase kinase-3β activity and reduction of tau hyperphosphorylation. This intervention also preserved neuronal viability and attenuated neuroinflammation, highlighting the feasibility of adiponectin-mimetic therapies that cross the blood–brain barrier to counteract key features of Alzheimer-type pathology.

Metabolic Disorders and Neurodegenerative Disease Interactions publication trend

The graph below shows the total number of articles in metabolic disorders and neurodegenerative disease interactions across all publications each year (not limited to Nature Index journals).

Technical terms

Adipokine: A hormone secreted by adipose tissue that regulates energy balance, insulin sensitivity and inflammation.

NLRP3-inflammasome: A multi-protein complex in microglia and other cells that activates inflammatory cytokines in response to stress signals.

Blood–brain barrier: A selective endothelial interface that controls exchange of substances between the circulation and the central nervous system.

Insulin resistance: A reduced cellular response to insulin that impairs glucose uptake and disrupts metabolic signalling in peripheral tissues and the brain.

PI3K/Akt pathway: A key intracellular signalling cascade involved in cell survival, synaptic plasticity and metabolic regulation.

References

1. Liver-specific adiponectin gene therapy suppresses microglial NLRP3-inflammasome activation for treating Alzheimer’s disease. Journal of Neuroinflammation (2024).
2. Ovariectomy and High Fat-Sugar-Salt Diet Induced Alzheimer's Disease/Vascular Dementia Features in Mice. Aging and Disease (2024).
3. Inflammation and Oxidative Stress: The Molecular Connectivity between Insulin Resistance, Obesity, and Alzheimer’s Disease. Mediators of Inflammation (2015).
4. Alzheimer‐associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Molecular Medicine (2015).
5. Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus. Scientific Reports (2015).